This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About Anika (ANIK) Rating Upgrade to Buy
by Zacks Equity Research
Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Anika (ANIK) Loses -19.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Anika (ANIK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of -97.22% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Anika Therapeutics (ANIK) closed at $26.62 in the latest trading session, marking a -0.89% move from the prior day.
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Anika Therapeutics (ANIK) closed the most recent trading day at $31.37, moving +1.32% from the previous trading session.
Anika Therapeutics (ANIK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Anika Therapeutics (ANIK) closed at $31.13, marking a +1.83% move from the previous day.
Anika (ANIK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.
Anika Therapeutics (ANIK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Anika Therapeutics (ANIK) closed at $31.41 in the latest trading session, marking a +0.74% move from the prior day.
Anika Therapeutics (ANIK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Anika Therapeutics (ANIK) closed at $31.68, marking a +1.51% move from the previous day.
Anika Therapeutics (ANIK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Anika Therapeutics (ANIK) closed the most recent trading day at $30.07, moving -1.92% from the previous trading session.
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
by Zacks Equity Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of -20.83% and 10.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review
by Zacks Equity Research
The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
by Zacks Equity Research
Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.